0001225208-21-004302.txt : 20210302 0001225208-21-004302.hdr.sgml : 20210302 20210302173525 ACCESSION NUMBER: 0001225208-21-004302 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210227 FILED AS OF DATE: 20210302 DATE AS OF CHANGE: 20210302 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DAMELIO FRANK A CENTRAL INDEX KEY: 0001194004 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-03619 FILM NUMBER: 21705469 MAIL ADDRESS: STREET 1: C/O PFIZER INC. STREET 2: 235 EAST 42ND ST. CITY: NEW YORK STATE: NY ZIP: 10017 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 235 E 42ND ST CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 2125732323 MAIL ADDRESS: STREET 1: 235 E 42ND ST CITY: NEW YORK STATE: NY ZIP: 10017 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 4 1 doc4.xml X0306 4 2021-02-27 0000078003 PFIZER INC PFE 0001194004 DAMELIO FRANK A PFIZER INC.-CORP. SECRETARY 235 EAST 42ND ST. NEW YORK NY 10017 1 Executive Vice President Common Stock 2021-02-27 4 M 0 152785.0000 22.3500 A 607441.0000 D Common Stock 2021-02-27 4 F 0 27381.0000 33.4900 D 580060.0000 D Common Stock 2021-02-27 4 F 0 96872.0000 34.6400 D 483188.0000 D Stock Appreciation Rights 22.3500 2021-02-27 4 M 0 152785.0000 0.0000 D 2021-02-27 2021-02-27 Common Stock 152785.0000 0.0000 D The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Price is the closing price of Pfizer common stock on February 26, 2021. The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. In connection with the completed spinoff and combination of the Upjohn business with Mylan to create Viatris, and in accordance with their terms, adjustments were made to stock units, by providing additional Pfizer total shareholder return units (Stock Appreciation Rights) to plan participants in lieu of the Viatris dividend provided to shareholders, in order to maintain the same value post-transaction as the value of the outstanding awards prior to the transaction (subject to rounding). Susan E. Grant, by power of atty., for Frank A. D'Amelio 2021-03-02